These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31468995)

  • 1. Use of rivaroxaban in patients attending a hematology unit in clinical practice.
    Sebastián OG; Fernández MI; Fernández RM; Bernal LP
    Future Cardiol; 2019 Sep; 15(5):347-353. PubMed ID: 31468995
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticoagulation with rivaroxaban in a hematology unit: clinical profile, events and discontinuation rates in real-life patients with nonvalvular atrial fibrillation.
    Gavín Sebastián O; Izuzquiza Fernández M; Martínez Fernández R; Palomera Bernal L
    Future Cardiol; 2018 May; 14(3s):25-30. PubMed ID: 29848092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke.
    Cerezo-Manchado JJ; Navarro-Almenzar B; Elvira-Ruiz G; García-Candel F; Flores-Blanco PJ; Caro-Martínez C; Manzano-Fernández S; García-Iniesta N; Sánchez-García J; Cabañas-Perianes V; Moraleda-Jiménez JM
    Future Cardiol; 2018 May; 14(3s):31-37. PubMed ID: 29848091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain.
    Muñiz Lobato S; Tarrazo Tarrazo C; González Fernández E; Morán Alcalá M
    Future Cardiol; 2018 May; 14(3s):17-24. PubMed ID: 29848093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice.
    Brun Guinda D; Callen García Ó; Ondiviela Pérez J; Gracia Aznarez M; Artero Bello P; Rivero Fernandez E; Marquina Barcos A; Villarroel Salcedo M
    Future Cardiol; 2018 May; 14(3s):39-45. PubMed ID: 29848090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice.
    Pérez Cabeza AI; González Correa JA; Chinchurreta Capote PA; Bravo Marqués R; Ruiz Mateas F; Rosas Cervantes G; Mesa Prado F; López Tejero S; Valle Alberca A
    Future Cardiol; 2018 May; 14(3s):9-16. PubMed ID: 29848094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain.
    Martí E; Segado A; Pastor-Galán I; Amat P; Remigia MJ; Solano C; Navarro B
    Future Cardiol; 2018 May; 14(3s):3-8. PubMed ID: 29848095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
    Caro Martinez C; Cerezo Manchado JJ; Flores Blanco PJ; Elvira Ruíz G; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Andrés Pascual Figal D; Bailén Lorenzo JL; Navarro-Almenzar B; García-Candel F; Manzano Fernández S
    Curr Med Res Opin; 2019 Aug; 35(8):1463-1471. PubMed ID: 30912682
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?
    Pimentel Quezada Y; Bonilla Palomas JL; Gámez López AL; Moreno Conde M; López Ibáñez MC; Gallego de la Sacristana López-Serrano Á
    Future Cardiol; 2018 May; 14(3s):47-53. PubMed ID: 29848089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rivaroxaban at Non-Valvular Atrial Fibrillation: a Prospective Study and Clinical Practice].
    Fonyakin AV
    Kardiologiia; 2016 Aug; 56(8):87-92. PubMed ID: 28290887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem.
    Bartlett JW; Renner E; Mouland E; Barnes GD; Kuo L; Ha NB
    Ann Pharmacother; 2019 Jan; 53(1):21-27. PubMed ID: 30099888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Hsueh YH; Izem R; Southworth MR; Wei Y; Liao J; Goulding MR; Mott K; Chillarige Y; MaCurdy TE; Worrall C; Kelman JA
    JAMA Intern Med; 2016 Nov; 176(11):1662-1671. PubMed ID: 27695821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHA
    Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
    Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
    Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Kuhls S; van Eickels M; Turpie AG;
    Eur Heart J; 2016 Apr; 37(14):1145-53. PubMed ID: 26330425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.